Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010–2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screening

IF 4.5 3区 医学 Q2 IMMUNOLOGY Vaccine Pub Date : 2025-03-15 DOI:10.1016/j.vaccine.2025.126986
Susan Yuill , Michaela T. Hall , Michael Caruana , Gigi Lui , Louiza S. Velentzis , Megan A. Smith , C. David Wrede , Deborah Bateson , Karen Canfell
{"title":"Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010–2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screening","authors":"Susan Yuill ,&nbsp;Michaela T. Hall ,&nbsp;Michael Caruana ,&nbsp;Gigi Lui ,&nbsp;Louiza S. Velentzis ,&nbsp;Megan A. Smith ,&nbsp;C. David Wrede ,&nbsp;Deborah Bateson ,&nbsp;Karen Canfell","doi":"10.1016/j.vaccine.2025.126986","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Treatment of cervical precancer may be associated with an increased risk of adverse pregnancy outcomes. Australia introduced routine quadrivalent HPV vaccination (HPV4) in 2007, switching to nonavalent vaccination (HPV9) in 2018, and 5-yearly HPV screening in December 2017. We estimated the impact of HPV vaccination and HPV screening on precancer treatments, and thus on future preterm births (PTBs) and low birth weight (LBW) infants.</div></div><div><h3>Methods</h3><div>Using a model of HPV infection, natural history, cervical screening and precancer treatment, coupled with a Monte-Carlo model of fertility and obstetric outcomes, we estimated rates and numbers of precancer cervical treatments, PTBs and LBW infants in women with singleton pregnancies in Australia from 2010 to 2070. These outcomes were estimated for four scenarios: i) a base scenario, assuming the current HPV screening and vaccination programs; and three alternative scenarios: ii) future twice-lifetime screening in cohorts offered HPV9; (iii) no HPV vaccination program introduced (counterfactual); and (iv) HPV4 was never replaced with HPV9 (counterfactual).</div></div><div><h3>Results</h3><div>Precancer treatment rates are predicted to decrease by 82 % between 2010 and 2070 in the context of HPV9 vaccination and ongoing 5-yearly screening, with an additional 42 % reduction by changing to twice-lifetime screening in HPV9 cohorts. An estimated 800,388 treatments would be averted over 2010–2070 by HPV9 compared to no vaccination, 80 % of these due to vaccine protection against HPV16/18. These treatment reductions will result in 22,441 (32,011) fewer PTBs (LBW infants) over 2010–2070 due to vaccine protection against HPV16/18, and a further 4359 (6298) due to vaccine protection against HPV31/33/45/52/58. An additional 3174 (4621) events would be averted with future twice-lifetime screening in HPV9 cohorts.</div></div><div><h3>Conclusion</h3><div>This analysis demonstrates that the benefits of HPV vaccination programs extend beyond prevention of HPV-related disease. HPV vaccination will reduce PTBs and LBW infants, with a further reduction with future twice-lifetime screening for HPV9 cohorts.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 126986"},"PeriodicalIF":4.5000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X2500283X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Treatment of cervical precancer may be associated with an increased risk of adverse pregnancy outcomes. Australia introduced routine quadrivalent HPV vaccination (HPV4) in 2007, switching to nonavalent vaccination (HPV9) in 2018, and 5-yearly HPV screening in December 2017. We estimated the impact of HPV vaccination and HPV screening on precancer treatments, and thus on future preterm births (PTBs) and low birth weight (LBW) infants.

Methods

Using a model of HPV infection, natural history, cervical screening and precancer treatment, coupled with a Monte-Carlo model of fertility and obstetric outcomes, we estimated rates and numbers of precancer cervical treatments, PTBs and LBW infants in women with singleton pregnancies in Australia from 2010 to 2070. These outcomes were estimated for four scenarios: i) a base scenario, assuming the current HPV screening and vaccination programs; and three alternative scenarios: ii) future twice-lifetime screening in cohorts offered HPV9; (iii) no HPV vaccination program introduced (counterfactual); and (iv) HPV4 was never replaced with HPV9 (counterfactual).

Results

Precancer treatment rates are predicted to decrease by 82 % between 2010 and 2070 in the context of HPV9 vaccination and ongoing 5-yearly screening, with an additional 42 % reduction by changing to twice-lifetime screening in HPV9 cohorts. An estimated 800,388 treatments would be averted over 2010–2070 by HPV9 compared to no vaccination, 80 % of these due to vaccine protection against HPV16/18. These treatment reductions will result in 22,441 (32,011) fewer PTBs (LBW infants) over 2010–2070 due to vaccine protection against HPV16/18, and a further 4359 (6298) due to vaccine protection against HPV31/33/45/52/58. An additional 3174 (4621) events would be averted with future twice-lifetime screening in HPV9 cohorts.

Conclusion

This analysis demonstrates that the benefits of HPV vaccination programs extend beyond prevention of HPV-related disease. HPV vaccination will reduce PTBs and LBW infants, with a further reduction with future twice-lifetime screening for HPV9 cohorts.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Vaccine
Vaccine 医学-免疫学
CiteScore
8.70
自引率
5.50%
发文量
992
审稿时长
131 days
期刊介绍: Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.
期刊最新文献
Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010–2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screening Are health education effective to improve herpes zoster vaccine willingness in vulnerable elderly Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine Applying the health belief model (HBM) to understand COVID-19 vaccine uptake among youth and young adults: Findings from a 6-month follow-up study in the United States Association of serum anti-gbs2106 protein immunoglobulin G (IgG) in newborns and risk reduction of invasive group B streptococcus disease during early infancy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1